Department of Pulmonary Medicine, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou 325000, China.
Clin Transl Med. 2014 Feb 10;3(1):2. doi: 10.1186/2001-1326-3-2.
Because of the economic growth and changes in lifestyle, metabolic diseases have become a major public health problem, which impose heavy economic burdens on individuals, families and health systems. However, its precise mediators and mechanisms remain to be fully understood. Clinical translational medicine (CTM) is an emerging area comprising multidisciplinary research from basic science to medical applications and as a new tool to improve human health by reducing disease incidence, morbidity and mortality. It can bridge knowledge of metabolic diseases processes, gained by in vitro and experimental animal models, with the disease pathways found in humans, further to identify their susceptibility genes and enable patients to achieve personalized medicament treatment. Thus, we have the reasons to believe that CTM will play even more roles in the development of new diagnostics, therapies, healthcare, and policies and the Sino-American Symposium on Clinical and Translational Medicine (SAS-CTM) will become a more and more important platform for exchanging ideas on clinical and translational research and entails a close collaboration among hospital, academia and industry.
由于经济增长和生活方式的改变，代谢性疾病已成为一个主要的公共卫生问题，给个人、家庭和卫生系统带来了沉重的经济负担。然而，其确切的介质和机制仍有待充分理解。临床转化医学（CTM）是一个新兴领域，包括从基础科学到医学应用的多学科研究，是通过降低疾病发病率、发病率和死亡率来改善人类健康的新工具。它可以将通过体外和实验动物模型获得的代谢性疾病过程知识与在人类中发现的疾病途径联系起来，进一步确定其易感基因，并使患者能够实现个体化药物治疗。因此，我们有理由相信，CTM 将在新的诊断、治疗、医疗保健和政策的发展中发挥更大的作用，而中美临床与转化医学研讨会（SAS-CTM）将成为一个越来越重要的交流临床和转化研究思想的平台，并需要医院、学术界和工业界之间的密切合作。
